Email updates

Keep up to date with the latest news and content from DARU Journal of Pharmaceutical Sciences and BioMed Central.

Open Access Highly Accessed Editorial

Drug-drug co-crystals

Bhupinder Singh Sekhon

Author Affiliations

PCTE Institute of Pharmacy, near Baddowal Cantt, Ludhiana, 142 021, India

DARU Journal of Pharmaceutical Sciences 2012, 20:45  doi:10.1186/2008-2231-20-45

Published: 4 October 2012

First paragraph (this article has no abstract)

Active pharmaceutical ingredients (APIs) are most conveniently developed and delivered orally as solid dosage forms that contain a defined crystalline form of an API. Co-crystal is a crystalline entity formed by two different or more molecular entities where the intermolecular interactions are weak forces like hydrogen bonding and π-π stacking. Co-crystals are an enabling technology that is used in new or existing drug delivery systems by majority of pharmaceutical companies in formulation and drug development. The concept of modifying the properties of a drug molecule by forming a pharmaceutical co-crystal containing a single APIs and a pharmaceutical relevant co-former with improved properties compared with the pure drug crystal has generated immense interest [1]. Physicians prescribe combination therapy frequently to treat and manage a plethora of medical conditions. Multi-API co-crystals, relatively unexplored solid forms of APIs, have potential relevance in the context of combination drugs for pharmaceutical drug development (Figure 1).